Although prostate cancer is initially often successfully targeted with androgen deprivation therapy or AR antagonists such as enzalutamide, drug- and castration-resistant AR mutants or splice variants are often developed within patients with prostate cancer (25, 87, 88). This evidence concerns the gene AR and prostate cancer.